Evidence map›Paper›PMID 42620702›Full record

ArticleFrontiers in immunology2026

Modeling antibody recognition across SARS-CoV-2 and SARS-CoV-1 using epitope-informed transfer learning.

Jimmy B Yuan, Ryan C Bruneau, Stephen Won, Aidan Elliot Heller, Thomas Sheffield, Kenneth L Sale, Brooke Harmon, Le Thanh Mai Pham

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jimmy B Yuan *Biotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA, United States.
Ryan C Bruneau *Biotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA, United States.
Stephen WonBiotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA, United States.
Aidan Elliot HellerBioresource and Environmental Security, Sandia National Laboratories, Livermore, CA, United States.
Thomas SheffieldBiosecurity and Bioassurance, Sandia National Laboratories, Livermore, CA, United States.
Kenneth L SaleBiosecurity and Bioassurance, Sandia National Laboratories, Livermore, CA, United States.
Brooke HarmonBiotechnology and Bioengineering, Sandia National Laboratories, Livermore, CA, United States.
Le Thanh Mai PhamBioresource and Environmental Security, Sandia National Laboratories, Livermore, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiviral antibody discovery is constrained by the enormous combinatorial space of antibody paratopes and viral epitopes, while novel approaches to search for these vast possibilities such as machine learning models for antibody affinity prediction typically require large target-specific datasets that are rarely available for emerging pathogens. To address this problem, we investigated the ability of transfer learning to reduce the required training data and still create a robust predictive model of antibody affinities. We show that antibody-affinity prediction can be locally transferred from a data-rich viral target to a related data-limited viral target by combining transfer learning, epitope-centered antigen encoding, antibody CDR descriptors, and targeted experimental validation. Using SARS-CoV-2 receptor-binding-domain (RBD) interaction data as the source domain, we developed dual-encoder neural-network models that capture functional determinants of antibody recognition and supports prediction of SARS-CoV-1 variant:antibody affinities despite limited direct training data. High-throughput ELISA measurements generated compact validation datasets spanning heavy-chain-only antibodies (HCAbs) and conventional antibodies, enabling iterative model refinement through similarity-guided, model-informed data expansion. Across expanded withheld-antibody evaluations, the final models showed improved but antibody-dependent predictive performance, with mean Pearson correlations of 0.71 ± 0.12 for SARS-CoV-2 and 0.63 ± 0.09 for SARS-CoV-1, and best-performing holdouts reaching 0.85 and 0.78, respectively. These results demonstrate that existing immunological datasets can support feature-constrained transfer learning for data-efficient prioritization of antibody:antigen interactions across closely related Sarbecoviruses, particularly when conserved epitope regions can be aligned and limited target-specific measurements are available for calibration.

Indexed as

Antibodies, ViralCOVID-19EpitopesSARS-CoV-2Antibody AffinityHumansNeural Networks, ComputerSpike Glycoprotein, CoronavirusAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody: antigen interactionantibody prioritizationcomputational immunologyepitope modelingSarbecovirusSARS-CoV-1SARS-CoV-2transfer learning

Identifiers

PMID42620702
PMCPMC13485751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.